Comparative binding of disulfide-bridged PEG-Fabs

Bioconjugate Chemistry

Volumn 23, Issue 11, 2012, Pages 2262-2277

  Khalili, Hanieh ^a,b   Godwin, Antony ^b   Choi, Ji Won ^b   Lever, Rebecca ^a   Brocchini, Steve ^a,b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b Antitope Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; BINDING SITES; CARDIOVASCULAR SYSTEM; CHROMATOGRAPHIC ANALYSIS; ION CHROMATOGRAPHY; ION EXCHANGE; LIGANDS; MONOCLONAL ANTIBODIES;

ASSOCIATION RATES; BEVACIZUMAB; BIACORE; BINDING AFFINITIES; BINDING STUDIES; DERIVED PRODUCTS; PEGYLATED; PEGYLATION; SITE-SPECIFIC; TRASTUZUMAB;

SULFUR COMPOUNDS;

BEVACIZUMAB; DISULFIDE; DITHIOTHREITOL; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL; PAPAIN; RANIBIZUMAB; SULFONE; SULFUR; TRASTUZUMAB; VASCULOTROPIN 165;

ALKYLATION; ARTICLE; BINDING AFFINITY; BINDING SITE; CONJUGATION; CONTROLLED STUDY; DISSOCIATION; DRUG STABILITY; IMMOBILIZATION; ION EXCHANGE CHROMATOGRAPHY; LIGAND BINDING; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DEGRADATION; PURIFICATION;

EID: 84869803398     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300372r     Document Type: Article

References (92)

1. Elbakri, A., Nelson, P. N., and Abu Odeh, R. O. (2010) The state of antibody therapy Hum. Immunol. 71 (12) 1243-1250
2. Holliger, P. and Hudson, P. J. (2005) Engineered antibody fragments and the rise of single domains Nat. Biotechnol. 23 (9) 1126-1136
3. Nelson, A. L. and Reichert, J. M. (2009) Development trends for therapeutic antibody fragments Nat. Biotechnol. 27 (4) 1-7
4. Fischer, N. and Leger, O. (2007) Bispecific antibodies: Molecules that enable novel therapeutic strategies Pathobiology 74 (1) 3-14
5. Gebauer, M. and Skerra, A. (2009) Engineered protein scaffolds as next-generation antibody therapeutics Curr. Opin. Chem. Biol. 13 (3) 245-255
6. Boersma, Y. L. and Plückthun, A. (2011) Darpins and other repeat protein scaffolds: Advances in engineering and applications Curr. Opin. Biotechnol. 22 (6) 849-857
7. Lipovsek, D. (2011) Adnectins: Engineered target-binding protein therapeutics Protein Eng. 24 (1-2) 3-9
8. Schellekens, H. (2002) Immunogenicity of therapeutic proteins: Clinical implications and future prospects Clin. Ther. 24 (11) 1720-1740
9. Farrell, R. A., Marta, M., Gaeguta, A. J., Souslova, V., Giovannoni, G., and Creeke, P. I. (2012) Development of resistance to biologic therapies with reference to ifn- Rheumatology 51 (4) 590-599
10. Giezen, T., Mantel-Teeuwisse, A., Straus, S., Schellekens, H., Leufkens, H., and Egberts, A. (2008) Safety-related regulatory actions for biologicals approved in the united states and the european union J. Am. Med. Assoc. 300 (16) 1887-1896
11. Singh, S. K. (2011) Impact of product-related factors on immunogenicity of biotherapeutics J. Pharm. Sci. 100 (2) 354-387
12. Bailon, P. and Won, C. (2009) Peg-modified biopharmaceuticals Expert Opin. Drug Delivery 6 (1) 1-16
13. Hamidi, M., Rafiei, P., and Azadi, A. (2008) Designing pegylated therapeutic molecules: Advantages in admet properties Expert Opin. Drug Discovery 3 (11) 1293-1307
14. Jevsevar, S., Kunstelj, M., and Porekar, V. G. (2010) Pegylation of therapeutic proteins Biotechnol. J. 5 (1) 113-128
15. Smith, P., Krohn, R., Hermanson, G., Mallia, A., Gartner, F., Provenzano, M., Fujimoto, E., Goeke, N., Olson, B., and Klenk, D. (1985) Measurement of protein using bicinchoninic acid Anal. Biochem. 150, 76-85
16. Payne, R. W., Murphy, B. M., and Manning, M. C. (2010) Product development issues for pegylated proteins Pharm. Dev. Technol. 1-18
17. Pisal, D. S., Kosloski, M. P., and Balu-Iyer, S. V. (2010) Delivery of therapeutic proteins J. Pharm. Sci. 99 (6) 2557-2575
18. Veronese, F. (2001) Peptide and protein pegylation a review of problems and solutions Biomaterials 22 (5) 405-417
19. Veronese, F. M. (2009) Pegylated protein drugs: Basic science and clinical applications. Milestones in drug therapy (Parnham, M. J., and and Bruinvels, J., Eds.) Birkhauser, Basel.
20. Harris, J. M. and Chess, R. B. (2003) Effect of pegylation on pharmaceuticals Nat. Rev. Drug Dis. 2 (3) 214-221
21. Kochendoerfer, G. G. (2005) Site-specific polymer modification of therapeutic proteins Curr. Opin. Chem. Biol. 9, 555-560
22. Pasut, G., Guiotto, A., and Veronese, F. M. (2004) Protein, peptide and non-peptide drug pegylation for therapeutic application Expert Opin. Ther. Pat. 14 (5) 1-36
23. Webster, R., Didier, E., Harris, P., Siegel, N., Stadler, J., Tilbury, L., and Smith, D. (2007) Pegylated proteins:Evaluation of their safety in the absence of definitive metabolism studies Drug Metab. Dispos. 35 (1) 9-16
24. Zalipsky, S. (1995) Chemistry of poly(ethylene glycol) conjugates with biologically active molecules Adv. Drug Delivery Rev. 16, 157-182
25. Roberts, M. J., Bentley, M. D., and Harris, J. M. (2002) Chemistry for peptide and protein pegylation Adv. Drug Delivery Rev. 54, 459-476
26. Rosendahl, M. S., Doherty, D. H., Smith, S. J., Carlson, S. J., Chlipala, E. A., and Cox, G. N. (2005) A long-acting, highly potent interferon a-2 conjugate created using site-specific pegylation Bioconjugate Chem. 16, 200-207
27. Doherty, D. H., Rosendahl, M. S., Smith, D. J., Hughes, J. M., Chlipala, E. A., and Cox, G. N. (2005) Site-specific pegylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor Bioconjugate Chem. 16 (5) 1291-1298
28. Mei, B., Pan, C., Jiang, H., Tjandra, H., Strauss, J., Chen, Y., Liu, T., Zhang, X., Severs, J., Newgren, J., Chen, J., Gu, J. M., Subramanyam, B., Fournel, M. A., Pierce, G. F., and Murphy, J. E. (2010) Rational design of a fully active, long-acting pegylated factor viii for hemophilia a treatment Blood 116 (2) 270-279
29. Yang, K., Basu, A., Wang, M., Chintala, R., Hsieh, M., Liu, S., Hua, J., Zhang, Z., Zhou, J., Li, M., Phyu, H., Petti, G., Mendez, M., Janjua, H., Peng, P., Longley, C., Borowski, V., Mehlig, M., and Filpula, D. (2003) Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific pegylation Protein Eng. 16 (10) 761-770
30. Mooler, I., Thomas, A., Geyer, H., Schanzer, W., and Thevis, M. (2011) Synthesis, characterisation, and mass spectrometric detection of a pegylated epo-mimetic peptide for sports drug testing purpose Rapid Commun. Mass Spectrom. 25, 2115-2123
31. Locatelli, F. and Vecchio, L. D. (2009) Hematide for the treatment of chronic kidney disease-related anemia Expert Rev. Hematol. 2 (4) 377-383
32. Nelson, A. L. (2010) Antibody fragments; hope and hype MABS 2 (1) 77-83
33. Tracey, D., Klereskog, L., Sasso, E. H., Salfeld, J. G., and Tak, P. P. (2008) Tumor necrosis factor antagonist mechanisms of action: A comprehensive review Pharmacol. Therapeut. 117, 244-279
34. Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., and Senter, P. D. (2008) Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjugate Chem. 19, 759-765
35. Shen, B. Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte1, K. L., Tien, J., Yu, S., Mai, E., Li, D., Tibbitts, J., Baudys, J., Saad, O. M., Scales, S. J., Mcdonald, P. J., Hass, P. E., Eigenbrot, C., Nguyen, T., Solis, W. A., Fuji, R. N., Flagella, K. M., Patel1, D., Spencer, S. D., Khawli, L. A., Ebens, A., Wong, W. L., Vandlen, R., Kaur1, S., Sliwkowski1, S. X., Scheller, R. H., Polakis, P., and Junutula1, J. R. (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 1-7
36. Shaunak, S., Godwin, A., Choi, J. W., Balan, S., Pedone, E., Vijayarangam, D., Heidelberger, S., Teo, I., Zloh, M., and Brocchini, S. (2006) Site-specific pegylation of native disulfide bonds in therapeutic proteins Nat. Chem. Biol. 312-313
37. Balan, S., Choi, J. W., Godwin, A., Teo, I., Laborde, C. M., Heidelberger, S., Zloh, M., Shaunak, S., and Brocchini, S. (2007) Site-specific pegylation of protein disulfide bonds using a three-carbon bridge Bioconjugate Chem. 18 (1) 61-76
38. Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., and Singh, R. J. (2007) Pharmacokinetics of intravitreal bevacizumab (avastin) Ophthalmology 114 (5) 855-859
39. Ferrara, N., Hillan, K. J., Gerber, H. P., and Novotny, W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat. Rev. Drug Discovery 3 (5) 391-400
40. Shih, T. and Lindley, C. (2006) Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies Clin. Ther. 28 (11) 1779-1802
41. Kubetzko, S., Sarkar, C. A., and Plückthun, A. (2005) Protein pegylation decreases observed target association rates via a dual blocking mechanism Mol. Pharmacol. 68 (5) 1439-1454
42. Mabry, R., Rani, M., Geiger, R., Hubbard, G. B., Carrion, R., Brasky, K., Patterson, J. L., Georgiou, G., and Iverson, B. L. (2005) Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region Infect. Immun. 73 (12) 8362-8368
43. Chapman, A. P. (2002) PEGylated antibodies and antibody fragments for improved therapy: A review Adv. Drug Delivery Rev. 54, 531-545
44. Gestwicki, J. E., Cairo, C. W., Mann, D. A., Owen, R. M., and Kiessling, L. L. (2002) Selective immobilization of multivalent ligands for surface plasmon resonance and fluorescence microscopy Anal. Biochem. 305 (2) 149-155
45. Colombo, M., Corsi, F., Foschi, D., Mazzantini, E., Mazzucchelli, S., Morasso, C., Occhipinti, E., Polito, L., Prosperi, D., Ronchi, S., and Verderio, P. (2010) HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches Pharmacol. Res. 62 (2) 150-165
46. Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., Jr, and Leahy, D. J. (2003) Structure of the extracellular region of HER2 alone and in complex with the herceptin Fab Nature 421 (6924) 753-756
47. Kubetzko, S., Balic, E., Waibel, R., Wittke, U. Z., and Pluckthun, A. (2006) Pegylation and multimeriztion of the anti-p185 HER2 single chain fv fragment 4d5 J. Biol. Chem. 281, 35186-35201
48. Johansson, B. P., Shannon, O., and Björck, L. (2008) Ides: A bacterial proteolytic enzyme with therapeutic potential PLoS ONE 3 (2) e1692
49. Vincents, B., Von Pawel-Rammingen, U., BjöRck, L., and Abrahamson, M. (2004) Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding Biochemistry 43, 15540-15549
50. Akesson, P., Moritz, L., Truedsson, M., Christensson, B., and Pawel-Rammingen, U. V. (2006) Ides, a highly specific immunoglobulin g (IgG)-cleaving enzyme from streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection Infect. Immun. 74 (1) 497-503
51. Scollard, D. A., Chan, C., Holloway, C. M. B., and Reilly, R. M. (2011) A kit to prepare 111in-dtpa-trastuzumab (herceptin) Fab fragments injection under gmp conditions for imaging or radioimmunoguided surgery of her2-positive breast cancer Nucl. Med. Biol. 38 (1) 129-136
52. Myszka, D. G. (1999) Improving biosensor analysis J. Mol. Recognit. 12, 279-284
53. Cresswell, C., Newcombe, A. P., Davies, S., Macpherson, I., Nelson, P., Apos, K. O., and Donovan, F. R. (2005) Optimal conditions for the papain digestion of polyclonal ovine IgG for the production of biotherapeutic Fab fragments Biotechnol. Appl. Biochem. 42 (2) 163
54. 2 fragments from monoclonal IgG of different rat IgG subclasses J. lmmunol. Methods 64 (1-2) 141-146
55. Mitchel, R. E., Chaiken, I. M., and Smith, E. L. (1970) The complete amino acid sequence of papain J. Biol. Chem. 245 (14) 3485-3492
56. Brocchini, S., Godwin, A., Balan, S., Choi, J. W., Zloh, M., and Shaunak, S. (2008) Disulfide bridge based pegylation of proteins Adv. Drug Delivery Rev. 3-12
57. Humphreys, D. P., Heywood, S. P., Henry, A., Ait-Lhadj, L., Antoniw, P., Palframan, R., Greenslade, K. J., Carrington, B., Reeks, D. G., Bowering, L. C., West, S., and Brand, H. A. (2007) Alternative antibody Fabs; fragment pegylation strategies: Combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering Protein Eng. Des. Sel. 20 (5) 227-234
58. 2 molecules made from escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model J. Immunol. Methods 217, 1-10
59. Begg, G. E. and Speicher, D. W. (1999) Mass spectrometry detection and reduction of disulfide adducts between reducing agents and recombinant proteins with highly reactive cysteines J. Biomol. Technol. 10, 17-20
60. Brocchini, S., Balan, S., Godwin, A., Choi, J. W., Zloh, M., and Shaunaik, S. (2006) Pegylation of native disulfide bonds in proteins Nat. Protoc. 1 (5) 2241-2252
61. Netto, L. E. S. and Stadtman, E. R. (1996) The iron-catalyzed oxidation of dithiothreitol is a biphasic process: Hydrogen peroxide is involved in the initiation of a free radical chain of reactions Arch. Biochem. Biophys. 330 (1) 233-242
62. Bjellqvist, B., Pasquali, C., Ravier, F., Sanchez, J., and Hochstrasser, D. (1993) A nonlinear wide-range immobilised ph gradient for two-dimensional electrophoresis and its definition in a relvent pH scale Electrophoresis 14, 1357-1365
63. Liu, H., Chumsae, C., Gaza-Bulseco, G., Hurkmans, K., and Radziejewski, C. H. (2010) Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and lc-ms analysis Anal. Chem. 1-8
64. Liu, X. Y., Pop, L. M., and Vitetta, E. S. (2008) Engineering therapeutic monoclonal antibodies Immunol. Rev. 222, 9-27
65. Cong, Y., Pawlisz, E., Bryant, P., Balan, S., Laurine, E., Tommasi, R., Singh, R., Dubey, S., Peciak, K., Bird, M., Sivasankar, A., Swierkosz, J., Muroni, M., Heidelberger, S., Farys, M., Khayrzad, F., Edwards, J., Badescu, G., Hodgson, I., Heise, C., Somavarapu, S., Liddell, J., Powell, K., Zloh, M., Choi, J.-W., Godwin, A., and Brocchini, S. (2012) Site-specific pegylation at histidine tags Bioconjugate Chem. 23 (2) 248-263
66. Knappik, A. and Brundiers, R. (2009) Recombinant antibody expression and purification, in The protein protocol handbook (Walker, J. M., Ed.) Springer, Berlin.
67. Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., and Trout, B. L. (2010) Prediction of aggregation prone regions of therapeutic proteins J. Phys. Chem. 114, 6614-6624
68. Sun, M. M. C., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G. M., Ihle, N. C., Senter, P. D., and Alley, S. C. (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides Bioconjugate Chem. 16 (5) 1282-1290
69. Karlsson, R., Hakan Roos, R., Fagerstam, L., and Persson, B. (1994) Kinetic and concentration analysis using bia technology Methods 6, 99-110
70. Myszka, D. G. (1997) Kinetic analysis of macro molecular interactions using surface plasmon resonance biosensors Curr. Opin. Biotechnol. 8, 50-57
71. Harding, S. E. and Chowdhry, B. Z., Eds. (2001) Surface plasmon resonance. In Protein-ligand interaction: Hydrodynamics and calorimetry, Oxford University Press, Oxford.
72. Liang, W., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H. P., Ferrara, N., and Fuh, G. (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the frowth of human tumor xenografts and measure the contribution of stormal VEGF J. Biol. Chem. 281 (2) 951-961
73. Patel, R. and Andrien, B. A. (2010) Kinetic analysis of a monoclonal therapeutic antibody and its single-chain homolog by surface plasmon resonance Anal. Biochem. 396 (1) 59-68
74. Chen, Y., Weismann, C., Fun, G., Li, B., Christinger, H. W., Mckay, P., M. De Vos, A., and Lowman, H. B. (1999) Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen J. Mol. Biol. 293, 865-881
75. Fuh, G., Wei-Ching, P. W., Mark, L., Chingwei, U., Moffat, V. L., and Wiesmann, C. (2006) Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab J. Biol. Chem. 281 (10) 6625-6631
76. Meyer, C. H. and Holz, F. G. (2011) Preclinical aspects of anti-VEGF agents for the treatment of wet amd: Ranibizumab and bevacizumab Eye 25 (6) 661-672
77. Lowe, J., Araujo, J., Yang, J., Reich, M., Oldendorp, A., Shiu, V., Quarmby, V., Lowman, H., Lien, S., Gaudreault, J., and Maia, M. (2007) Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo Exp. Eye Res. 85 (4) 425-430
78. Chen, C., Constantinou, A., and Deonarain, M. (2011) Modulating antibody pharmacokinetics using hydrophilic polymers Exp. Opin. Drug Delivery 8 (9) 1221-1236
79. Chapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S., and King, D. J. (1999) Therapeutic antibody fragments with prolonged in-vivo half-lives Nat. Biotechnol. 17, 780-783
80. Bobrovnik, S. A. (2003) Determination of antibody affinity by ELISA. Theory J. Biochem. Biophys. Methods 57 (3) 213-236
81. Regenmortel, M. H. V. and Azimzadeh, A. (2000) Determination of antibody affinity J. Immunoassay 211 (21) 211-234
82. Heinrich, L., Tissot, N., Hartmann, D. J., and Cohen, R. (2010) Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity J. Immunol. Methods 352 (1-2) 13-22
83. Baer, M., Sawa, T., Flynn, P., Luehrsen, K., Martinez, D., Wiener-Kronish, J. P., Yarranton, G., and Bebbington, C. (2009) An engineered human antibody Fab fragment specific for pseudomonas aeruginosa pcrv antigen has potent antibacterial activity Infect. Immun. 77 (3) 1083-1090
84. Pacchiana, G., Chiriaco, C., Stella, M. C., Petronzelli, F., De Santis, R., Galluzzo, M., Carminati, P., Comoglio, P. M., Michieli, P., and Vigna, E. (2010) Monovalency unleashes the full therapeutic potential of the dn-30 anti-met antibody J. Biol. Chem. 285 (46) 36149-36157
85. Vauquelin, G. and Charlton, S. J. (2010) Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action Br. J. Pharmacol. 161 (3) 488-508
86. Bostrom, J., Haber, L., Koenig, P., Kelley, R. F., and Fuh, G. (2011) High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity PLoS ONE 6 (4) e17887
87. Steffen, A.-C., Wikman, M., Tolmachev, V., Adams, G. P., Nilsson, F. Y., Ståhl, S., and Carlsson, J. (2005) In vitro characterization of a bivalent anti-her-2 affibody with potential for radionuclide-based diagnostics Cancer Biother. Radiopharm. 20 (3) 239-248
88. Godula, K., Umbel, M. L., Rabuka, D., Botyanszki, Z., Bertozzi, C. R., and Parthasarathy, R. (2009) Control of the molecular orientation of membrane-anchored biomimetic glycopolymers J. Am. Chem. Soc. 131 (29) 10263-10268
89. Howorka, S., Nam, J., Bayley, H., and Kahne, D. (2004) Stochastic detection of monovalent and bivalent protein-ligand interactions Angew. Chem., Int. Ed. 43 (7) 842-846
90. Kiessling, L. L., Gestwicki, J. E., and Strong, L. E. (2006) Synthetic multivalent ligands as probes of signal transduction Angew. Chem., Int. Ed. 45 (15) 2348-2368
91. Gestwicki, J. E., Cairo, C. W., Strong, L. E., Oetjen, K. A., and Kiessling, L. L. (2002) Influencing receptor-ligand binding mechanisms with multivalent ligand architecture J. Am. Chem. Soc. 124 (50) 14922-14933
92. Belardi, B., O'donoghue, G. P., Smith, A. W., Groves, J. T., and Bertozzi, C. R. (2012) Investigating cell surface galectin-mediated cross-linking on glycoengineered cells J. Am. Chem. Soc. 134 (23) 9549-9552